Site Search
Search Results
Comprehensive Genomic Testing for Lung Cancer Patients: Pathologist-Driven Solutions
LUNGevity and ACS CAN partnered with Bruce Quinn Associates to develop materials to engage hospitals on pathologist-initiated biomarker testing, providing an overview of the MolDx clarification on CMS "treating physician" guidance. Comprehensive Genomic Testing for Lung Cancer Patients: Pathologist-Driven Solutions ...
Survivor Views: One in Ten Impacted by Recent Drug Shortages
... our latest survey explores the impact of recent drug shortages on cancer patients and survivors, as well as experiences with telehealth and biomarker testing. The web-based survey was conducted among 1,222n cancer patients and survivors nationwide who have been diagnosed with or treated for ... substitute medications (68%), treatment delays (45%), and difficulties related to insurance coverage, such as coverage for an alternate therapy. Biomarker Testing Over three-quarters (77%) of survey respondents who have had biomarker testing agree that the results gave their provider ...